Get the Stockscreener App
24.63
1.99%
-0.50
After Hours:
24.70
0.07
+0.28%
Mineralys Therapeutics Inc stock is traded at $24.63, with a volume of 4.06M.
It is down -1.99% in the last 24 hours and down -6.67% over the past month.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
See More
Previous Close:
$25.13
Open:
$25.58
24h Volume:
4.06M
Relative Volume:
2.71
Market Cap:
$2.17B
Revenue:
-
Net Income/Loss:
$-151.78M
P/E Ratio:
-11.96
EPS:
-2.0595
Net Cash Flow:
$-136.42M
1W Performance:
+2.88%
1M Performance:
-6.67%
6M Performance:
-33.43%
1Y Performance:
+79.39%
1-Day Range:
$24.52
$25.99
1-Week Range:
$23.26
$25.99
52-Week Range:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
24.63 | 2.17B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | TD Cowen | Buy |
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics Inc (MLYS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mineralys Therapeutics Inc (MLYS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mineralys Therapeutics Inc (MLYS) Institutional Confidence - TradingKey
Mineralys: Limited Differentiation Makes Lorundrostat A Weak Competitor - Seeking Alpha
Mineralys Therapeutics Inc (MLYS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mineralys Therapeutics Inc (MLYS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mineralys Therapeutics director Karydas sells $75,000 in stock By Investing.com - Investing.com India
Mineralys Therapeutics (MLYS) CMO sells 14,474 shares, exercises options - Stock Titan
Director at Mineralys Therapeutics (MLYS) trades 3,000 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics CMO Rodman sells $350,086 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics director Karydas sells $75,000 in stock - Investing.com
Mineralys Therapeutics CMO Rodman sells $350,086 in stock - Investing.com
Mineralys Therapeutics Inc (MLYS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mineralys Therapeutics Inc (MLYS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mineralys Therapeutics Inc (MLYS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mineralys Therapeutics (NASDAQ: MLYS) files Form 144 to sell 4,584 shares - Stock Titan
Mineralys Therapeutics (MLYS) Rule 144: 3,000-share cashless exercise - Stock Titan
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock - Yahoo Finance UK
The Technical Signals Behind (MLYS) That Institutions Follow - Stock Traders Daily
Mineralys Therapeutics (MLYS) affiliate lists multi-date sales and a 3,542-share exercise - Stock Titan
Mineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic Analysis - Quiver Quantitative
Mineralys Therapeutics Presents Late-Breaking Data on - GlobeNewswire
Mineralys Therapeutics (MLYS) CMO sells 8,519 shares after option exercises - Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) files Rule 144 disclosing 6,349‑share cashless exercise - Stock Titan
Akin, an Elite Global Law Firm - Akin
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat - Insider Monkey
Transcript : Mineralys Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02 - marketscreener.com
Mineralys Therapeutics Announces Royalty Repurchase, $500 Million Debt Facility, and $150 Million Equity Offering - Global Legal Chronicle
[144] Mineralys Therapeutics, Inc. SEC Filing - Stock Titan
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
MLYS: Lorundrostat advances toward launch with strong clinical data, strategic deals, and broad payer support - TradingView
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Biopharma Mineralys joins Goldman Sachs health-care talks in Miami - Stock Titan
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) - The Manila Times
Mineralys Therapeutics to Present Late-Breaking Data on - GlobeNewswire
Latham Advises Mineralys Therapeutics in Unique Three-Pronged Transaction — Royalty Repurchase, Debt Financing, and Equity Offering — Totaling Up to US$950 Million - Legal Desire Media and Insights
Mineralys Deepens Lorundrostat Bet With Royalty Buyout And New Data - Yahoo Finance
Mineralys Therapeutics Stock In Shambles: Down -25% With 6-Day Losing Streak - Trefis
Mineralys Therapeutics Stock Plummets 25% With 6-Day Losing Streak - Trefis
Precision Trading with Mineralys Therapeutics Inc. (MLYS) Risk Zones - Stock Traders Daily
Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy - Insider Monkey
10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds - Insider Monkey
Mineralys Therapeutics prices $150M stock offering - MSN
Latham Advises Mineralys Therapeutics in Unique Three-Pronged - Latham & Watkins LLP
Mineralys pays up to $300 million to clear lorundrostat royalties - The Pharma Letter
MLYS Stock Sees 17.1% Decline Amid Market Movements - GuruFocus
Mineralys announces $150 million equity offering and financing - TipRanks
Mineralys (Nasdaq: MLYS) prices $150M stock sale to fund $200M royalty buyback - Stock Titan
Mineralys (MLYS) raises ~$150M in $26.50/share offering to fund royalty repurchase - Stock Titan
Mineralys Prices $150 Million Stock Offering, Repurchases Lorundrostat Royalty Obligations - Moomoo
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):